Patient demographics, clinical response, and adverse events
Patient ID . | Age, y . | Sex . | Lymphoma . | Lymphoma category . | N of prior lines of therapy . | BRESP . | OR subgroup . | Grade ≥3 CRS . | Grade ≥3 NT . |
---|---|---|---|---|---|---|---|---|---|
1 | 66.5 | M | DLBCL | Aggressive | 3 | PR | OR | CRS | — |
2 | 63.5 | M | FL | Indolent | 6 | CR | OR | CRS | NT |
3 | 65.3 | M | DLBCL | Aggressive | 4 | PR | OR | CRS | — |
4 | 47.1 | M | DLBCL | Aggressive | 2 | PR | OR | — | — |
5 | 28.8 | M | DLBCL | Aggressive | 7 | PD | — | — | — |
6 | 62.7 | M | DLBCL | Aggressive | 7 | CR | OR | — | NT |
7 | 54.7 | M | DLBCL | Aggressive | 3 | PD | — | CRS | — |
8 | 28.6 | M | DLBCL | Aggressive | 2 | SD | — | — | — |
9 | 29.5 | M | PMBCL | Aggressive | 3 | SD | — | — | — |
10 | 40.4 | M | PMBCL | Aggressive | 2 | PD | — | — | NT |
11 | 67.8 | M | DLBCL | Aggressive | 3 | CR | OR | — | NT |
12 | 50.4 | M | MCL | Indolent | 1 | CR | OR | CRS | NT |
13 | 53.2 | M | DLBCL | Aggressive | 4 | CR | OR | CRS | NT |
14 | 67.0 | F | FL | Indolent | 3 | CR | OR | CRS | NT |
15 | 51.9 | M | DLBCL | Aggressive | 3 | CR | OR | CRS | NT |
16 | 52.0 | F | DLBCL | Aggressive | 5 | CR | OR | CRS | NT |
17 | 39.0 | M | DLBCL | Aggressive | 4 | PR | OR | CRS | NT |
18 | 67.1 | F | DLBCL | Aggressive | 4 | CR | OR | CRS | NT |
19 | 64.4 | M | DLBCL | Aggressive | 4 | CR | OR | CRS | NT |
20 | 52.0 | M | DLBCL | Aggressive | 5 | PD | — | CRS | — |
Patient ID . | Age, y . | Sex . | Lymphoma . | Lymphoma category . | N of prior lines of therapy . | BRESP . | OR subgroup . | Grade ≥3 CRS . | Grade ≥3 NT . |
---|---|---|---|---|---|---|---|---|---|
1 | 66.5 | M | DLBCL | Aggressive | 3 | PR | OR | CRS | — |
2 | 63.5 | M | FL | Indolent | 6 | CR | OR | CRS | NT |
3 | 65.3 | M | DLBCL | Aggressive | 4 | PR | OR | CRS | — |
4 | 47.1 | M | DLBCL | Aggressive | 2 | PR | OR | — | — |
5 | 28.8 | M | DLBCL | Aggressive | 7 | PD | — | — | — |
6 | 62.7 | M | DLBCL | Aggressive | 7 | CR | OR | — | NT |
7 | 54.7 | M | DLBCL | Aggressive | 3 | PD | — | CRS | — |
8 | 28.6 | M | DLBCL | Aggressive | 2 | SD | — | — | — |
9 | 29.5 | M | PMBCL | Aggressive | 3 | SD | — | — | — |
10 | 40.4 | M | PMBCL | Aggressive | 2 | PD | — | — | NT |
11 | 67.8 | M | DLBCL | Aggressive | 3 | CR | OR | — | NT |
12 | 50.4 | M | MCL | Indolent | 1 | CR | OR | CRS | NT |
13 | 53.2 | M | DLBCL | Aggressive | 4 | CR | OR | CRS | NT |
14 | 67.0 | F | FL | Indolent | 3 | CR | OR | CRS | NT |
15 | 51.9 | M | DLBCL | Aggressive | 3 | CR | OR | CRS | NT |
16 | 52.0 | F | DLBCL | Aggressive | 5 | CR | OR | CRS | NT |
17 | 39.0 | M | DLBCL | Aggressive | 4 | PR | OR | CRS | NT |
18 | 67.1 | F | DLBCL | Aggressive | 4 | CR | OR | CRS | NT |
19 | 64.4 | M | DLBCL | Aggressive | 4 | CR | OR | CRS | NT |
20 | 52.0 | M | DLBCL | Aggressive | 5 | PD | — | CRS | — |
The table depicts major demographic characteristics of the evaluable patients.
BRESP, best response by Cheson et al11 criteria; CR, complete response; FL, follicular lymphoma; MCL, mantle cell lymphoma; PD, progressive disease; PMBCL, primary mediastinal B-cell lymphoma; PR, partial response; SD, stable disease.